Pulmonary Tumor With Notochordal Differentiation: Report of 2 Cases Suggestive of Benign Notochordal Cell Tumor of Extraosseous Origin

Department of Diagnostic Pathology, Chiba University Graduate School of Medicine, Chiba, Japan.
The American journal of surgical pathology (Impact Factor: 5.15). 06/2011; 35(8):1158-64. DOI: 10.1097/PAS.0b013e318220e085
Source: PubMed


Intraosseous benign notochordal cell tumor (BNCT) is a lesion postulated to be of notochordal cell origin. BNCT has recently been recognized as a potential precursor of classic chordoma, a rare malignant neoplasm usually presenting in the sacrococcygeal region, skull base, or mobile spine. Extra-axial chordoma is extremely rare, and only 2 cases of pulmonary chordoma have been reported previously. We describe herein 2 cases of hitherto-unreported lung tumors that were diagnosed as BNCT. The patients were a middle-aged asymptomatic man and woman who were each incidentally found to have a 15-mm pulmonary nodule on computed tomography. They underwent surgical resection of the tumors under a diagnosis of probable benign tumor of uncertain nature. Histopathologically, both tumors showed solid sheets of peculiar adipocyte-like univacuolated cells, multivacuolated cells, and less vacuolated cells with small, round nuclei and mildly eosinophilic cytoplasm. Mitosis was absent. These features were typical of BNCT. Immunohistochemically, the tumor cells in both cases were positive for brachyury, a transcription factor essential for notochordal cell differentiation and for other markers of notochordal cells including cytokeratins, vimentin, and S-100 protein. Postoperatively, extensive radiographic examination of the whole body revealed no evidence of a primary tumor elsewhere, and both patients are alive and well, with no evidence of disease 1 year after surgery. These 2 cases raise the possibility of a new explanation for the histogenesis of extra-axial chordomas: BNCT may be a precursor lesion of not only conventional axial chordoma but also of extra-axial chordoma.

2 Reads
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Chordoma is a rare malignant tumour of bone showing notochordal differentiation with characteristic expression of the transcription factor brachyury (T). Next to giving insight into its differentiation spectrum, the expression of T can be used as an adjunct diagnostic tool. The expression of brachyury in chordoma is necessary to maintain cell proliferation in chordoma cell lines, indicating that in chordoma it might be a master regulator of oncogenesis. Identification and mapping of the full gene regulatory network in a recent work in The Journal of Pathology by Nelson and colleagues not only shed light on involved pathways but also indicated pathways for targeted therapy, including brachyury itself.
    The Journal of Pathology 11/2012; 228(3):261-5. DOI:10.1002/path.4102 · 7.43 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Intraosseous benign notochordal cell tumors are rare and the likely precursors of chordoma. Extraosseous benign notochordal cell tumors have been reported in only 2 patients, and both presented as solitary pulmonary nodules. Here, we report a 53-year-old woman with an incidental finding of small nodules bilaterally in the lungs. The clinician suggested the tumors were metastases; however, histologic examination of both tumors showed benign notochordal cell tumor, characterized by adipocyte-like vacuolated cells with bland nuclei and lacking an intercellular myxoid matrix. Although extraosseous benign notochordal cell tumors are extremely rare, the diagnosis should be recognized by pathologists to avoid overtreatment of patients.
    Human pathology 03/2013; 44(7). DOI:10.1016/j.humpath.2012.10.028 · 2.77 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Soft tissue chordomas (STCs) have never been systematically studied because of their rarity and the difficulty in separating them from similar-appearing lesions. Using brachyury to confirm the diagnosis, we have analyzed our experience with 11 cases. Cases coded as "chordoma" or "parachordoma" were retrieved from institutional and consultation files (1989 to 2011) and were excluded from further analysis if they arose from the bone or in a patient with previous axial chordoma. Eleven of 27 cases met inclusion criteria. Patients (8 male; 3 female) ranged in age from 13 to 71 years (mean 44 y). Tumors were located on the buttock (n=2), wrist (n=2), leg (n=2), toe (n=1), thumb (n=1), ankle (n=1), shoulder (n=1), and chest wall (n=1), ranged in size from 0.5 to 10.9 cm (mean 5.3 cm), and consisted of cords and syncytia of spindled/epithelioid cells with vacuolated eosinophilic cytoplasm and a partially myxoid background. Tumors expressed brachyury (10/10), 1 or more cytokeratins (11/11), and S100 protein (10/11). Follow-up information was available for 10 patients (69 mo; range, 2 to 212 mo). Most (n=6) were alive without disease, 2 developed local recurrence and lung metastases, and 1 developed lung metastasis only. One died with unknown disease status. STCs are histologically identical to osseous ones, but differ in their greater tendency to occur in distal locations where small size and surgical resectability result in better disease control. The existence of STC implies that notochordal remnants are not a prerequisite for chordoma development.
    The American journal of surgical pathology 05/2013; 37(5):719-26. DOI:10.1097/PAS.0b013e31827813e7 · 5.15 Impact Factor
Show more